Myriad Genetics, Inc. $MYGN Shares Purchased by Invesco Ltd.

Invesco Ltd. lifted its position in Myriad Genetics, Inc. (NASDAQ:MYGN) by 19.1% during the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 916,520 shares of the company’s stock after acquiring an additional 147,236 shares during the period. Invesco Ltd. owned 0.99% of Myriad Genetics worth $8,130,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors have also recently made changes to their positions in MYGN. Barclays PLC boosted its stake in shares of Myriad Genetics by 7.3% in the fourth quarter. Barclays PLC now owns 204,051 shares of the company’s stock worth $2,797,000 after acquiring an additional 13,808 shares during the last quarter. MetLife Investment Management LLC boosted its stake in shares of Myriad Genetics by 6.2% in the fourth quarter. MetLife Investment Management LLC now owns 54,931 shares of the company’s stock worth $753,000 after acquiring an additional 3,231 shares during the last quarter. Tower Research Capital LLC TRC boosted its stake in shares of Myriad Genetics by 629.2% in the fourth quarter. Tower Research Capital LLC TRC now owns 28,264 shares of the company’s stock worth $387,000 after acquiring an additional 24,388 shares during the last quarter. Hsbc Holdings PLC boosted its stake in shares of Myriad Genetics by 49.4% in the fourth quarter. Hsbc Holdings PLC now owns 30,214 shares of the company’s stock worth $413,000 after acquiring an additional 9,997 shares during the last quarter. Finally, Voya Investment Management LLC boosted its stake in shares of Myriad Genetics by 25.5% in the fourth quarter. Voya Investment Management LLC now owns 47,782 shares of the company’s stock worth $655,000 after acquiring an additional 9,701 shares during the last quarter. 99.02% of the stock is owned by institutional investors and hedge funds.

Myriad Genetics Stock Down 2.2%

NASDAQ:MYGN opened at $5.89 on Tuesday. Myriad Genetics, Inc. has a 52 week low of $3.76 and a 52 week high of $29.30. The company has a market capitalization of $548.01 million, a P/E ratio of -1.38 and a beta of 1.89. The stock’s fifty day moving average is $5.17 and its two-hundred day moving average is $7.09.

Analyst Upgrades and Downgrades

MYGN has been the topic of a number of research analyst reports. Wolfe Research lowered Myriad Genetics from an “outperform” rating to a “peer perform” rating in a research note on Thursday, May 8th. UBS Group lowered their price objective on Myriad Genetics from $16.00 to $7.00 and set a “neutral” rating on the stock in a research note on Wednesday, May 7th. The Goldman Sachs Group lowered their price objective on Myriad Genetics from $14.00 to $8.00 and set a “buy” rating on the stock in a research note on Wednesday, May 7th. Scotiabank lowered Myriad Genetics from a “sector outperform” rating to a “sector perform” rating and lowered their price objective for the stock from $20.00 to $6.00 in a research note on Wednesday, May 21st. Finally, Craig Hallum set a $18.00 price objective on Myriad Genetics and gave the stock a “buy” rating in a research note on Wednesday, May 7th. Four analysts have rated the stock with a Buy rating, nine have given a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of “Hold” and a consensus target price of $12.45.

Myriad Genetics Profile

Myriad Genetics, Inc, a genetic testing and precision medicine company, develops genetic tests in the United States and internationally. The company offers molecular diagnostic tests for use in oncology, and women's and pharmacogenomics. It also provides MyRisk Hereditary Cancer Test, a DNA sequencing test for assessing the risks for hereditary cancers; BRACAnalysis CDx Germline Companion Diagnostic Test, a DNA sequencing test to help determine the therapy for patients with metastatic breast, ovarian, metastatic pancreatic, and metastatic prostate cancer with deleterious or suspected deleterious germline BRCA variants; and MyChoice CDx Companion Diagnostic Test, a tumor test that determines homologous recombination deficiency status in patients with ovarian cancer.